We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+10.09%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$176M
AUM Growth
+$4.87M
Cap. Flow
-$868K
Cap. Flow %
-0.49%
Top 10 Hldgs %
54.6%
Holding
85
New
17
Increased
11
Reduced
21
Closed
12

Top Buys

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$3.05M
2
CMPS
Compass Pathways
CMPS
+$2.52M
3
ENGN icon
enGene Therapeutics
ENGN
+$2.23M
4
RLMD icon
Relmada Therapeutics
RLMD
+$1.94M
5
CLDX icon
Celldex Therapeutics
CLDX
+$1.91M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$3.6M
2
KLAC icon
KLA
KLAC
+$2.93M
3
CSTL icon
Castle Biosciences
CSTL
+$2.22M
4
IMNM icon
Immunome
IMNM
+$1.78M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 73.14%
2 Technology 21.04%
3 Energy 4.89%
4 Materials 0.6%
5 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PACB icon
26
Pacific Biosciences
PACB
$447M
$1.98M 1.13%
1,500,000
+1,000,000
+200% +$1.79M
CYTK icon
27
Cytokinetics
CYTK
$10.9B
$1.98M 1.13%
30,000
– –
CORT icon
28
Corcept Therapeutics
CORT
$9.72B
$1.9M 1.08%
47,200
-20,000
-30% -$748K
VERA icon
29
Vera Therapeutics
VERA
$2.76B
$1.77M 1.01%
44,000
– –
ALKS icon
30
Alkermes
ALKS
$8.79B
$1.77M 1.01%
50,000
– –
ENGN icon
31
enGene Therapeutics
ENGN
$122M
$1.7M 0.97%
+250,000
New +$2.23M
QURE icon
32
uniQure
QURE
$2.77B
$1.65M 0.94%
100,697
+69,908
+227% +$1.42M
ZBIO
33
Zenas BioPharma
ZBIO
$1.86B
$1.37M 0.78%
+70,000
New +$1.57M
QDEL icon
34
QuidelOrtho
QDEL
$1.19B
$1.36M 0.77%
82,548
+10,000
+14% +$246K
FHTX icon
35
Foghorn Therapeutics
FHTX
$305M
$1.35M 0.77%
281,730
– –
RARE icon
36
Ultragenyx Pharmaceutical
RARE
$2.88B
$1.3M 0.74%
62,000
– –
XENE icon
37
Xenon Pharmaceuticals
XENE
$6.6B
$1.22M 0.7%
21,000
– –
KALV
38
DELISTED
KalVista Pharmaceuticals
KALV
$1.15M 0.65%
57,000
– –
IMNM icon
39
Immunome
IMNM
$2.53B
$1.09M 0.62%
50,000
-80,000
-62% -$1.78M
FCX icon
40
Freeport-McMoran
FCX
$83.9B
$1.06M 0.6%
18,040
-6
-0% -$363
AXSM icon
41
Axsome Therapeutics
AXSM
$11.8B
$1.01M 0.58%
6,000
-61
-1% -$10.5K
BIIB icon
42
Biogen
BIIB
$30.4B
$917K 0.52%
+5,000
New +$921K
LPCN icon
43
Lipocine
LPCN
$18.4M
$893K 0.51%
+111,786
New +$974K
TVTX icon
44
Travere Therapeutics
TVTX
$5.27B
$868K 0.49%
29,200
-13,800
-32% -$413K
HROW icon
45
Harrow
HROW
$1.74B
$846K 0.48%
24,000
-10,000
-29% -$440K
PHVS icon
46
Pharvaris
PHVS
$2.44B
$843K 0.48%
29,847
– –
VSTM icon
47
Verastem
VSTM
$530M
$795K 0.45%
150,000
– –
APGE icon
48
Apogee Therapeutics
APGE
$10.1B
$758K 0.43%
9,000
-7,000
-44% -$508K
HALO icon
49
Halozyme
HALO
$9.23B
$653K 0.37%
10,100
– –
BBIO icon
50
BridgeBio Pharma
BBIO
$15.9B
$645K 0.37%
8,688
– –
1
2
3 4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Birchview Capital held 85 positions worth $176M, up 2.8% from $171M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Birchview Capital's Q1 2026 filing shows 17 new, 11 increased, 21 reduced and 12 closed positions. Its largest new stake was Ocular Therapeutix: 320,000 shares worth $2.71M. The largest sale was Amicus Therapeutics, an estimated $3.6M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 76% a quarter earlier, followed by Technology and Energy.

  • Birchview Capital's largest Q1 2026 buy was Ocular Therapeutix: 320,000 shares worth $2.71M.
  • Birchview Capital added most to Pacific Biosciences in Q1 2026, an estimated $1.79M increase.
  • Birchview Capital's biggest Q1 2026 reduction was KLA, cutting an estimated $2.93M.
  • Birchview Capital fully exited Amicus Therapeutics in Q1 2026, selling an estimated $3.6M.
  • Birchview Capital's ten largest holdings make up 55% of its $176M portfolio in Q1 2026.
  • Birchview Capital opened 17 new positions and closed 12 in Q1 2026.
  • Birchview Capital's portfolio value rose 2.8% quarter-over-quarter to $176M.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.